PTC Therapeutics Q2 Revenue Beats Modestly, Sephience Outlook in Focus, Morgan Stanley Says

MT Newswires Live

08/08

PTC Therapeutics (PTCT) Q2 net product revenue and royalties came in modestly ahead of expectations, Morgan Stanley said in a Friday note.

Morgan Stanley added that PTC Therapeutics' unchanged 2025 revenue guidance reflected some uncertainty around the contribution from new product launches.

The lower end of the guidance contemplating rapid Emflaza genericization, while the higher end reflects successful new product approvals, including Sephience, a newly approved treatment for sepiapterin-responsive phenylketonuria.

On Thursday, PTC Therapeutics posted better-than-expected Q2 results and continued to expect 2025 revenue to be between $650 million and $800 million.

Morgan Stanley has a overweight rating on the company and raised its price target to $76 from $70 on Q2 results and updated Sephience assumptions following its recent approvals in the US and Europe.

Shares of PTC Therapeutics were down 7% in recent trading.

Price: 46.85, Change: -3.51, Percent Change: -6.97

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2558752035"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2558752035\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2558752035?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-08 23:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2558752035","market":"sh","top_or_hot":-1,"title":"PTC Therapeutics Q2 Revenue Beats Modestly, Sephience Outlook in Focus, Morgan Stanley Says","media":"MT Newswires Live","content":"<html><body><p> PTC <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (PTCT) Q2 net product revenue and royalties came in modestly ahead of expectations, <a href=\"https://laohu8.com/S/MTK\">Morgan Stanley</a> said in a Friday note.</p><p>Morgan Stanley added that PTC Therapeutics' unchanged 2025 revenue guidance reflected some uncertainty around the contribution from new product launches.</p><p>The lower end of the guidance contemplating rapid Emflaza genericization, while the higher end reflects successful new product approvals, including Sephience, a newly approved treatment for sepiapterin-responsive phenylketonuria.</p><p>On Thursday, PTC Therapeutics posted better-than-expected Q2 results and continued to expect 2025 revenue to be between $650 million and $800 million.</p><p>Morgan Stanley has a overweight rating on the company and raised its price target to $76 from $70 on Q2 results and updated Sephience assumptions following its recent approvals in the US and Europe.</p><p>Shares of PTC Therapeutics were down 7% in recent trading.</p><p>Price: 46.85, Change: -3.51, Percent Change: -6.97</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>PTC Therapeutics Q2 Revenue Beats Modestly, Sephience Outlook in Focus, Morgan Stanley Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPTC Therapeutics Q2 Revenue Beats Modestly, Sephience Outlook in Focus, Morgan Stanley Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-08-08 23:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> PTC <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (PTCT) Q2 net product revenue and royalties came in modestly ahead of expectations, <a href=\"https://laohu8.com/S/MTK\">Morgan Stanley</a> said in a Friday note.</p><p>Morgan Stanley added that PTC Therapeutics' unchanged 2025 revenue guidance reflected some uncertainty around the contribution from new product launches.</p><p>The lower end of the guidance contemplating rapid Emflaza genericization, while the higher end reflects successful new product approvals, including Sephience, a newly approved treatment for sepiapterin-responsive phenylketonuria.</p><p>On Thursday, PTC Therapeutics posted better-than-expected Q2 results and continued to expect 2025 revenue to be between $650 million and $800 million.</p><p>Morgan Stanley has a overweight rating on the company and raised its price target to $76 from $70 on Q2 results and updated Sephience assumptions following its recent approvals in the US and Europe.</p><p>Shares of PTC Therapeutics were down 7% in recent trading.</p><p>Price: 46.85, Change: -3.51, Percent Change: -6.97</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PTC","symbol_name":"PTC Inc.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2558752035","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2558752035","pubTimestamp":1754667814,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"PTC Therapeutics  Q2 net product revenue and royalties came in modestly ahead of expectations, Morgan Stanley said in a Friday note.Morgan Stanley added that PTC Therapeutics' unchanged 2025 revenue guidance reflected some uncertainty around the contribution from new product launches.The lower end of the guidance contemplating rapid Emflaza genericization, while the higher end reflects successful new product approvals, including Sephience, a newly approved treatment for sepiapterin-responsive phenylketonuria.On Thursday, PTC Therapeutics posted better-than-expected Q2 results and continued to expect 2025 revenue to be between $650 million and $800 million.Morgan Stanley has a overweight rating on the company and raised its price target to $76 from $70 on Q2 results and updated Sephience assumptions following its recent approvals in the US and Europe.Shares of PTC Therapeutics were down 7% in recent trading.Price: 46.85, Change: -3.51, Percent Change: -6.97","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"PTC":"PTC Inc.","PTCT":"PTC Therapeutics Inc."},"translate_title":"摩根士丹利表示，PTC Therapeutics第二季度收入小幅增长，Sefience前景成为焦点","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PTC":1,"PTCT":1},"content_text":"PTC Therapeutics (PTCT) Q2 net product revenue and royalties came in modestly ahead of expectations, Morgan Stanley said in a Friday note.Morgan Stanley added that PTC Therapeutics' unchanged 2025 revenue guidance reflected some uncertainty around the contribution from new product launches.The lower end of the guidance contemplating rapid Emflaza genericization, while the higher end reflects successful new product approvals, including Sephience, a newly approved treatment for sepiapterin-responsive phenylketonuria.On Thursday, PTC Therapeutics posted better-than-expected Q2 results and continued to expect 2025 revenue to be between $650 million and $800 million.Morgan Stanley has a overweight rating on the company and raised its price target to $76 from $70 on Q2 results and updated Sephience assumptions following its recent approvals in the US and Europe.Shares of PTC Therapeutics were down 7% in recent trading.Price: 46.85, Change: -3.51, Percent Change: -6.97","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}